BiotechTube
Inipharm

Inipharm

Seattle, United States· Est.
inipharm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $160M

Overview

Inipharm is a private, clinical-stage biotech based in Seattle, advancing a pipeline centered on inhibiting HSD17B13, a target with strong human genetic validation for liver disease. Its lead candidate, INI-822, is a first-in-class small molecule inhibitor currently in Phase 1 trials, including cohorts with MASH (Metabolic dysfunction-Associated Steatohepatitis) patients. The company is led by a seasoned team with deep experience in liver disease drug development and biotech entrepreneurship, aiming to address significant unmet needs in fibrotic liver diseases.

Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)Fibrotic Diseases

Technology Platform

Small-molecule drug discovery platform focused on inhibiting the genetically-validated target HSD17B13, leveraging human genetic data to de-risk development for severe liver diseases.

Funding History

2
Total raised:$160M
Series B$100M
Series A$60M

Opportunities

The massive and growing unmet need in MASH, a multi-billion dollar market with few approved therapies, presents a major opportunity.
The strong human genetic validation of HSD17B13 across multiple liver diseases could enable expansion into additional indications like alcohol-associated liver disease.

Risk Factors

High clinical risk that INI-822 may not demonstrate efficacy or safety in patients despite genetic validation.
Significant pipeline concentration risk with all value tied to one target.
Intense competition in the MASH space from companies with greater resources.

Competitive Landscape

Inipharm competes in the crowded MASH/therapeutics arena against large pharma (e.g., Madrigal, Novo Nordisk, Gilead) and numerous biotechs. Its key differentiator is being first-in-class targeting HSD17B13, a mechanism with direct human genetic proof-of-concept, unlike many other approaches.

More companies in Small Molecule Drugs →More companies in United States →